Nealanjon Das, DO
Nephrology · Newark, DENPI 1528163649
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 275 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$995
- Amgen$677
- Fresenius USA Marketing, Inc.$578
- Mallinckrodt Hospital Products Inc.$530
- Otsuka America Pharmaceutical, Inc.$338
- Vifor Pharma, Inc.$303
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,49297%
- Education$1463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 42 | $995 |
| Amgen(2 entities) | 31 | $677 |
| Fresenius USA Marketing, Inc. | 32 | $578 |
| Mallinckrodt Hospital Products Inc. | 23 | $530 |
| Otsuka America Pharmaceutical, Inc. | 17 | $338 |
| Vifor Pharma, Inc. | 18 | $303 |
| Novo Nordisk | 13 | $253 |
| Sanofi | 13 | $235 |
| Bayer | 10 | $211 |
| Calliditas Therapeutics US Inc. | 9 | $183 |
| Novartis | 7 | $164 |
| Ardelyx, Inc. | 7 | $126 |
| Daiichi Sankyo Inc. | 7 | $113 |
| GSK | 7 | $109 |
| Aurinia Pharma U.S., Inc. | 4 | $100 |
| Medtronic | 1 | $85 |
| Travere Therapeutics, Inc. | 5 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Boehringer Ingelheim | 3 | $64 |
| OPKO Pharmaceuticals, LLC | 3 | $63 |
| Akebia Therapeutics Inc | 3 | $59 |
| Kyowa Kirin, Inc. | 3 | $59 |
| Mallinckrodt Enterprises LLC | 3 | $44 |
| Scpharmaceuticals Inc. | 2 | $41 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| Potrero Medical, Inc. | 1 | $22 |
| Nxstage Medical, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Daxor Corporation | 1 | $10 |
How this compares
$5,638 in reported general payments places this provider in the 75th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 57 | $72,839 |
| FarxigaDapagliflozin Propanediol | 36 | $54,227 |
| OzempicSemaglutide | 48 | $52,498 |
| RybelsusSemaglutide | 24 | $28,258 |
| LokelmaSodium Zirconium Cyclosilicate | 25 | $27,713 |
| KerendiaFinerenone | 13 | $23,529 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $19,808 |
| Bydureon BciseExenatide Microspheres | 14 | $11,395 |
| Potassium Citrate ErPotassium Citrate | 22 | $3,169 |
| Calcitriol | 77 | $2,614 |
| Sevelamer Carbonate | 16 | $1,904 |
| Amlodipine Besylate | 139 | $1,497 |
| Hydralazine Hcl | 46 | $1,430 |
| Losartan Potassium | 109 | $1,429 |
| Nifedipine ErNifedipine | 26 | $1,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $995 | $81,94061 claims |
| Novo NordiskOzempic, Rybelsus | $253 | $80,75672 claims |
| Boehringer IngelheimJardiance | $64 | $72,83957 claims |
| BayerKerendia | $211 | $23,52913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 49 nephrology providers in Delaware.
Other nephrology in Newark
- Prayus TailorNewark$127K
- William DahmsNewark$94K
- Theodore SaadNewark$26K
- Manthodi FaisalNewark$6K
- Piyaporn ApivatanagulNewark$5K
- Lindsey SlaterNewark$4K
- Christopher CanfieldNewark$3K
- Farhana ChowdhuryNewark$3K
- Feroz Abubacker KaniyamparambilNewark$3K
- Carlos MachadoNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.